OBJECTIVES: To evaluate efficacy, safety (concerning hypernatremia), and usage of UFO® in a medical center METHODS: A retrospective medical record review was conducted for patients who is treated with UFO® in Wan-fang hospital during 2012/5/1 to 7/8. Patients with cancers were excluded. Patients with suspected or diagnosed infections and more than one dose of UFO® were included. For hypernatremia analysis, only included patients with serum sodium level and no hypernatremia events prior UFO use. Microsoft excels and student t-test were utilized for analyzing data and p-values RESULTS: Thirty-eight patients were included and the common infection types are pneumonia (N=13); UTI (N=12); cellutitis (N=9) and sepsis (N=9). The common pathogens are Staphylococci (19%) and Pseudomona species (21%). Twenty-one percent of cases used UFO® as empirical or first-line therapy. Combination therapies with cephalosporins (26%) or penicillins (24%) were more frequent. In cephalosporins combinination therapy, the most combined antibiotics are 3th cephalosporins (75%). In penicillins combinination therapy, the most combined antibiotics is oxacillin (40%). Mean treatment duration of UFO is 9.4 days. There were 71% cases using common dose of UFO®, 8-12 g/day, and 29% using low dose, 4-6 g/day. In patients with UFO®, 74% had negative outcomes (defined as patient died, hypernatremia events and changed to other antibiotics) and 26% had positive outcomes (defined as patients discharged, disease improved and no recurrent fever). Most patients developed hypernatremia (serum sodium level >145 mEq/L) after using UFO^® for 4-6 days; patients with creatinine clearance above 50 ml/min did not develop hypernatremia. CONCLUSIONS: The serum sodium level didn’t increase significantly until day 4-6 after starting UFO®. For patients with higher baseline serum sodium level and renal dysfunction, sodium level should be monitored closely while using UFO®. Using UFO® as adjunct for first line or empiric treatments is lack of evidence. Further antibiotic prescribing regulations should be implemented concerning prescribing UFO®.